We are live on !
Find out more
Jim Simons Renaissance Technologies
AUM
$72.6B
Turnover
31.08%
1-Year Est. Return
54.88%
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
This Fund
S&P 500
This Quarter Est. Return
+24.48%
1 Year Est. Return
+54.88%
3 Year Est. Return
+169.34%
5 Year Est. Return
+186.18%
10 Year Est. Return
+887.93%
AUM
$72.6B
AUM Growth
+$8.69B
(+14%)
Cap. Flow
+$958M
Cap. Flow % of AUM
Cap. Flow %
1.32%
Top 10 Holdings %
Top 10 Hldgs %
12.01%
Holding
3,761
New
548
Increased
1,084
Reduced
1,502
Closed
621
Avg Time Held
3.5
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 2 |
NVIDIA
NVDA
|
+$938M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$639M |
| 4 |
Netflix
NFLX
|
+$598M |
| 5 |
Amazon
AMZN
|
+$575M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$1.46B |
| 2 |
Sandisk
SNDK
|
+$1.13B |
| 3 |
Apple
AAPL
|
+$426M |
| 4 |
Linde
LIN
|
+$316M |
| 5 |
Vertiv
VRT
|
+$297M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.58% |
| 2 | Healthcare | 14.83% |
| 3 | Consumer Discretionary | 11.24% |
| 4 | Industrials | 10.49% |
| 5 | Communication Services | 8.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2876
Connect Biopharma Holdings
CNTB
$55.1M
| $208K | ﹤0.01% |
87,300
-33,400
| -28% | -$81K |
2021 Q4
18 quarters
|
|
2877
Scully Royalty
SRL
$70.8M
| $206K | ﹤0.01% |
67,114
-1,000
| -1% | -$6.98K |
2013 Q2
52 quarters
|
|
2878
Kyntra Bio
KYNB
$21.4M
| $204K | ﹤0.01% |
27,081
-400
| -1% | -$2.8K |
2024 Q3
7 quarters
|
|
2879
Perspective Therapeutics
CATX
$263M
| $202K | ﹤0.01% |
+59,133
| New | +$223K |
2026 Q2
0 quarters
|
|
2880
Atrium Therapeutics
RNA
$137M
| $201K | ﹤0.01% |
+14,971
| New | +$196K |
2026 Q2
0 quarters
|
|
2881
Galectin Therapeutics
GALT
$346M
| $201K | ﹤0.01% |
43,343
-104,557
| -71% | -$271K |
2026 Q1
1 quarter
|
|
2882
Rockwell Medical
RMTI
$29.1M
| $198K | ﹤0.01% |
35,967
-27,945
| -44% | -$221K |
2019 Q4
26 quarters
|
|
2883
Elutia
ELUT
$35.9M
| $198K | ﹤0.01% |
201,816
+119,100
| +144% | +$126K |
2023 Q1
13 quarters
|
|
2884
Global X NASDAQ-100 Covered Call ETF
QYLD
$8.36B
| $197K | ﹤0.01% |
+10,700
| New | +$192K |
2026 Q2
0 quarters
|
|
2885
RLJ Lodging Trust
RLJ
$1.85B
| $197K | ﹤0.01% |
16,600
-282,632
| -94% | -$2.64M |
2025 Q2
4 quarters
|
|
2886
Rafael Holdings
RFL
$67.1M
| $196K | ﹤0.01% |
59,815
-29,323
| -33% | -$47.1K |
2018 Q1
33 quarters
|
|
2887
Wetouch Technology
WETH
$12.5M
| $195K | ﹤0.01% |
161,558
+105,058
| +186% | +$161K |
2024 Q4
6 quarters
|
|
2888
Defiance Daily Target 2X Long RGTI ETF
RGTX
$23.9M
| $193K | ﹤0.01% |
+10,425
| New | +$243K |
2026 Q2
0 quarters
|
|
2889
Treace Medical Concepts
TMCI
$265M
| $192K | ﹤0.01% |
48,300
-474,600
| -91% | -$1.3M |
2026 Q1
1 quarter
|
|
2890
ACCESS Newswire
ACCS
$17.5M
| $190K | ﹤0.01% |
29,238
-100
| -0.3% | -$722 |
2020 Q2
24 quarters
|
|
2891
Cocrystal Pharma
COCP
$18.2M
| $189K | ﹤0.01% |
179,628
+55,700
| +45% | +$68.5K |
2019 Q3
27 quarters
|
|
2892
Integra LifeSciences
IART
$1.04B
| $189K | ﹤0.01% |
+10,500
| New | +$147K |
2026 Q2
0 quarters
|
|
2893
Outset Medical
OM
$79.3M
| $188K | ﹤0.01% |
43,428
-178,647
| -80% | -$781K |
2024 Q3
7 quarters
|
|
2894
Genasys
GNSS
$60.6M
| $187K | ﹤0.01% |
109,936
+800
| +0.7% | +$1.5K |
2014 Q3
47 quarters
|
|
2895
Silence Therapeutics
SLN
$1.22B
| $186K | ﹤0.01% |
+16,930
| New | +$119K |
2026 Q2
0 quarters
|
|
2896
Exagen
XGN
$180M
| $184K | ﹤0.01% |
39,600
-163,672
| -81% | -$616K |
2025 Q4
2 quarters
|
|
|
WKEY
2897
DELISTED
WISeKey
WKEY
| $182K | ﹤0.01% |
+24,925
| New | +$195K |
2026 Q2
0 quarters
|
|
2898
Bridgeline Digital
BLIN
$8.65M
| $182K | ﹤0.01% |
156,729
-2,000
| -1% | -$1.99K |
2020 Q4
22 quarters
|
|
2899
a.k.a. Brands
AKA
$111M
| $182K | ﹤0.01% |
16,969
-600
| -3% | -$6.03K |
2021 Q4
18 quarters
|
|
2900
Cibus
CBUS
$106M
| $182K | ﹤0.01% |
132,500
+33,600
| +34% | +$48K |
2025 Q3
3 quarters
|
|
Similar funds
Jim Simons's Q2 2026 Portfolio in Review
As of Q2 2026, Jim Simons held 3,761 positions worth $72.6B, up 14% from $63.9B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q2 2026 filing shows 548 new, 1,084 increased, 1,502 reduced and 621 closed positions. Its largest new stake was Amazon: 2,290,710 shares worth $546M. The largest sale was Micron Technology, an estimated $1.46B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q2 2026 buy was Amazon: 2,290,710 shares worth $546M.
- Jim Simons added most to Meta Platforms (Facebook) in Q2 2026, an estimated $1.08B increase.
- Jim Simons's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $1.46B.
- Jim Simons fully exited Applovin in Q2 2026, selling an estimated $174M.
- Jim Simons's ten largest holdings make up 12% of its $72.6B portfolio in Q2 2026.
- Jim Simons opened 548 new positions and closed 621 in Q2 2026.
- Jim Simons's portfolio value rose 14% quarter-over-quarter to $72.6B.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.